Back to News
Market Impact: 0.22
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Source: GlobeNewswire
Healthcare & BiotechCompany Fundamentals
Post hoc analyses of the SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to 8.6 mmol/L. The result is consistent with NBD1 biological activity, providing an encouraging biomarker signal for the cystic fibrosis candidate, though the analysis is exploratory.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
SION0.42
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- RBC Capital cuts Sprouts Farmers Market stock rating on margin concerns
- Microsoft's Big Bets on AI Start to Pay Off